AMLX Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Amylyx Pharmaceuticals (NASDAQ: AMLX)
›
Amylyx Pharmaceuticals (NASDAQ: AMLX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 136 employees.
The shares were at 26.20 USD on 19 November 2026, up 97.9% over 52 weeks. Its 52-week range is 10.83 USD to 41.13 USD: the price is 36.3% below the high and 141.9% above the low.
Its market capitalisation is 3.37B USD.
Amylyx Pharmaceuticals reports return on equity of -47.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 763.19M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 43.00 USD is 64.1% above the current price. The next earnings report is expected on 4 March 2027.